Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 98 clinical trials
Observational Real-life Study of Cabozantinib in Advanced Renal Cell Carcinoma (RCC)

The purpose of this study is to describe the real-life use of Cabometyx in Belgium and the Netherlands in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later lines of

  • 03 Apr, 2021
  • 23 locations
Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting

This is an international, multi-centre, prospective (partly retrospective), observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated with sunitinib in first line and/or receiving axitinib in second line post sunitinib. The study is designed to enroll approximately 750 patients over the course …

  • 24 Jan, 2021
  • 121 locations
Registry For Temsirolimus Sunitinib And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC) Mantle Cell Lymphoma (MCL) And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]

The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel, Sutent, and/or Inlyta therapies in patients with advanced renal cell carcinoma, recurrent / refractory mantle cell lymphoma (MCL) and gastro-intestinal stroma tumors (GIST) under the conditions of routine use

refractory mantle cell lymphoma
  • 25 Jan, 2021
  • 117 locations
Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CT

The incidence of renal cancer in Denmark is approximately 900 new cases per year. Untreated, the 5-year survival rate for metastatic renal cancer (mRCC) is 2%. Development of angiogenesis inhibitors (AI) and check-point immunotherapy (CPI) has improved survival. Treatment efficacy is evaluated by CT scans, using RESIST 1.1 (Response Evaluation …

  • 24 Jan, 2021
  • 1 location
CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective Non-interventional Study

This is a non-interventional study to retrospectively evaluate the safety and to describe the effectiveness of cabozantinib after immunoncologic treatment with nivolumab or nivolumab plus ipilimumab in routine clinical practice. It consists of a retrospective chart review of patients who have already completed treatment with cabozantinib after nivolumab or nivolumab …

  • 17 Feb, 2021
  • 3 locations
Nivolumab in mRCC Patients: Treg Function T-cell Access and NK Interactions to Predict and Improve Efficacy

The project aims to identify Nivolumab predictive biomarkers in metastatic renal cancer patients through functional evaluation of peripheral Tregs and NKs. Moreover the efficacy of new CXCR4 antagonists (PCT/IB2011/000120/ EP2528936B1/ US2013/0079292A1) will be ex vivo evaluated in modulating Tregs and NKs function

clear cell renal cell carcinoma
kidney cancer
metastatic renal cancer
  • 25 Jan, 2021
  • 1 location
TDM for Optimized Outcome in Patients With mRCC.

The purpose of this observational study is to assess the role of plasma concentration monitoring of treatment drugs for patients with metastatic renal cell carcinoma (mRCC) in terms of efficacy

  • 27 Jan, 2021
  • 3 locations
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer

This pilot research trial studies the use of the Myeloid Derived Suppressor Cells Clinical Assay in finding and monitoring kidney cancer. Studying samples of blood and urine from patients with kidney cancer in the laboratory may aid doctors in the early detection of cancer, monitor tumor response to therapy, detect …

neutrophil count
kidney cancer
metastatic renal cell carcinoma
  • 23 Jan, 2021
  • 1 location